Genetic Assessment of Early to Late Macular Degeneration Study

Age-related macular degeneration (AMD) is the leading cause of blindness in the developed
world. To date, two major polymorphisms on the HTRA1 and CFH genes have been associated with
AMD. Progression and vision loss need to be followed and treated promptly in order to
preserve vision. This study will provide more information on the genetics of disease
progression and may lead to future guidelines for patient follow-up and treatment.

This study consists of a blood draw and observation of eye conditions. Consented, enrolled
patients will come in every four months as per standard of care. At each visit, visual
acuity measurement, slit lamp exam, indirect ophthalmoscopy, fundus photos, and spectral
domain optical coherence tomography will be performed. Every 8 months, or per standard of
care, fluoroscein angiography will be performed. DNA extraction and genotyping will be
performed, and correlations between HTRA1 and CFH genotypes and the progression to bilateral
advanced AMD will be analyzed.

Inclusion Criteria:

- Subjects will be eligible if the following criteria are met:

- Ability to provide written informed consent and comply with study assessments for the
full duration of the study

- Age > 45 years

- Disease related considerations

- Subjects with a diagnosis of advanced AMD in one eye (either CNV or geographic
atrophy) and soft confluent drusen in the study eye OR subjects with bilateral large
soft drusen.

Exclusion Criteria:

- Subjects with any other progressive retinal disease that may impair the physician's
ability to assess the severity of AMD